Bambusa Therapeutics Inc (Nasdaq:BBTX), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, announced on Thursday the pricing of its upsized initial public offering of 10,555,555 shares of its common stock at a public offering price of USD16.00 per share.

Gross proceeds to Bambusa from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be USD168,888,880. Bambusa has also granted the underwriters a 30-day option to purchase up to an additional 1,583,333 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Bambusa.

Bambusa's common stock is expected to begin trading on the Nasdaq Global Select Market on 30 October 2026, under the ticker symbol 'BBTX'. The offering is expected to close on 2 November 2026, subject to the satisfaction of customary closing conditions.

BofA Securities, Evercore ISI, UBS Investment Bank and Cantor are acting as joint book-running managers for the offering.